Stoke Therapeutics, Inc. (STOK)

11,87 -0,15 (-1,25%) Alla chiusura: 04:00PM EDT

Stoke Therapeutics, Inc.

45 Wiggins Avenue
Bedford, MA 01730
United States
781 430 8200
https://www.stoketherapeutics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 110

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Edward M. Kaye M.D., Ph.D.	CEO & Director	948,9k	N/D	1949
Dr. Adrian R. Krainer Ph.D.	Co-Founder & Independent Director	44k	N/D	1959
Dr. Barry S. Ticho FACC, M.D., Ph.D.	Chief Medical Officer	684,55k	N/D	1961
Ms. Isabel Aznarez Ph.D.	Co-Founder & Group VP of Discovery Research	N/D	N/D	1973
Dr. Huw M. Nash Ph.D.	COO & Chief Business Officer	429,67k	N/D	1967
Mr. Eric Rojas	Head of Investor Relations	N/D	N/D	N/D
Mr. Jonathan Allan J.D.	Corporate Secretary & General Counsel	N/D	N/D	1990
Ms. Dawn Kalmar	Chief Communications Officer	N/D	N/D	1978
Ms. Joan Wood	Chief Human Resources Officer	N/D	N/D	N/D
Ms. Shamim Ruff M.S.	Chief Regulatory Officer	N/D	N/D	1960

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Stoke Therapeutics, Inc. al 1 maggio 2024 è 7. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 6; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.